Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Ronald Mitsuyasu, M.D.
Ronald Mitsuyasu, M.D.

Specialty:

Cancer/Medical Oncology
Hematology
Hematology/Oncology
Infectious Disease

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Director, CARE Center
Professor in Residence, Department of Medicine, Hematology/Oncology
Associate Director for Clinical Programs, UCLA AIDS Institute
Member, JCCC Tumor Immunology Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Hematology/Oncology, UCLA School of Medicine, 1981 - 1984
Residency:
Internal Medicine, Rush Presbyterian - St. Luke's Medical Center, 1979 - 1981
Internship:
Internal Medicine, Rush Presbyterian - St. Luke's Medical Center, 1978 - 1979
Medical Degree:
M.D., UCLA School of Medicine, 1978

Certification(s):

Medical Board Certification(s):
Internal Medicine, American Board of Internal Medicine, 1981
Professional Certification(s):
HIV Specialist, American Academy of HIV Medicine (AAHIVM)

Contact Information:

Hematology/Oncology:
(310) 206-6909 Information and patient appointments
CARE Center:
(310) 557-9680 Information and referral
(310) 557-2273 [(310) 557-CARE] Patient appointments
Email:
Website:

Scientific Interest(s):

Dr. Ronald Mitsuyasu has conducted research investigating new treatments for HIV and HIV associated malignancies since 1974. He is the director of the UCLA Center for Clinical AIDS Research and Education and has been involved in clinical trials of both antiretroviral drugs as well as immune-based therapies for HIV and complications of HIV. He is the group chair of the National Cancer Institute-sponsored AIDS Malignancy Consortium and conducts clinical trials for Kaposi's sarcoma, non-Hodgkin's lymphoma, anal cancer and anal and cervical precancerous lesions. He has and continues to be a major investigator of the role of Interleukin-2 and other cytokines and vaccines as treatment in HIV. He is a pioneer in the clinical evaluation of gene therapy for HIV and is principal investigator for an international Phase III gene therapy study, which is the first of its kind. He has clinical research experience and a background in hematology/oncology as well as in immunology and immunotherapeutics.

Selected Cancer-Related Publications:

Gopal S, Wood WA, Lee SJ, Shea TC, Naresh KN, Kazembe PN, Casper C, Hesseling PB, Mitsuyasu RT. Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Blood. 2012 May 31;119(22):5078-87. Epub 2012 Mar 28

Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, Koletar SL, Santana J, Sattler FR, Mitsuyasu R. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology. 2011 May 23;80(1-2):42-9. Epub 2011 May 23

Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010 Apr 15;115(15):3008-16. Epub 2009 Dec 18

Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R. Cancer biomarkers in HIV patients. Curr Opin HIV AIDS. 2010 Nov;5(6):531-7.

Chiao EY, Dezube BJ, Krown SE, Wachsman W, Brock MV, Giordano TP, Mitsuyasu R, Pantanowitz L. Time for oncologists to opt in for routine opt-out HIV testing? JAMA. 2010 Jul 21;304(3):334-9.